Please enable JavaScript to continue using this application.

Compare $KLRA vs $TSHA | Chartloom

Compare

$KLRA vs $TSHA

Kailera Therapeutics Inc · Taysha Gene Therapies Inc

KLRA

Kailera Therapeutics Inc

TSHA

Taysha Gene Therapies Inc

Compare $KLRA vs $TSHA

Comparing Kailera Therapeutics Inc and Taysha Gene Therapies Inc

KLRAKailera Therapeutics Inc

TSHATaysha Gene Therapies Inc

KLRAKailera Therapeutics Inc

Market cap

$1.50B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-55.3%

52W performance

-55.3%

FCF yield

0.0%

TSHATaysha Gene Therapies Inc

Market cap

$1.44B

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

664.56x

Rev growth (TTM)

-32.3%

YTD performance

-14.5%

52W performance

-11.3%

FCF yield

-9.2%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

KLRA

TSHA

Detailed metrics comparison

KLRA

Kailera Therapeutics Inc

TSHA

Taysha Gene Therapies Inc

Market Cap

KLRA$1.50B

TSHA$1.44B

Enterprise Value

KLRA$1.37B

TSHA$1.03B

Price

KLRA$11.61

TSHA$4.49

P/E Ratio

KLRAN/A

TSHAN/A

P/S Ratio

KLRA0.00x

TSHA261.77x

EV/Sales

KLRA0.00x

TSHA187.75x

EV/EBITDA

KLRA0.00x

TSHA0.00x

P/B Ratio

KLRA1.20x

TSHA3.90x

P/FCF Ratio

KLRAN/A

TSHAN/A

EV/FCF

KLRA0.00x

TSHA-7.77x

PEG Ratio

KLRAN/A

TSHAN/A

Forward P/E (NTM)

KLRAN/A

TSHAN/A

Forward P/S (NTM)

KLRAN/A

TSHA664.56x

Revenue (TTM)

KLRA$0

TSHA$5M

Revenue Growth (YoY)

KLRAN/A

TSHA-32.3%

Forward Rev Growth

KLRA275.8%

TSHA1272.3%

Gross Margin (TTM)

KLRA0.0%

TSHA0.0%

Operating Margin (TTM)

KLRA0.0%

TSHA0.0%

EBITDA Margin (TTM)

KLRA0.0%

TSHA-2833.6%

Net Margin (TTM)

KLRA0.0%

TSHA-2728.0%

FCF Margin (TTM)

KLRAN/A

TSHA-2417.0%

Net Income (TTM)

KLRA$-190M

TSHA$-150M

FCF (TTM)

KLRA$0

TSHA$-133M

EPS (TTM)

KLRA-$1.86

TSHA-$0.41

ROE (TTM)

KLRA0.0%

TSHA-5619.0%

ROA (TTM)

KLRA0.0%

TSHA-4184.0%

ROIC (TTM)

KLRA0.0%

TSHA-4729.0%

Cash

KLRA$130M

TSHA$455M

Debt

KLRA$0

TSHA$49M

Net Cash/Debt

KLRA$130M

TSHA$406M

Current Ratio (TTM)

KLRA11.11x

TSHA17.76x

Quick Ratio (TTM)

KLRA11.04x

TSHA17.57x

Debt/Equity (TTM)

KLRA0.00x

TSHA0.13x

Debt/Assets (TTM)

KLRA0.0%

TSHA0.0%

Interest Coverage (TTM)

KLRAN/A

TSHAN/A

Net Debt/EBITDA (TTM)

KLRA0.00x

TSHA0.00x

Beta

KLRA2.22

TSHA1.37

52W Performance

KLRA-55.3%

TSHA-11.3%

YTD Performance

KLRA-55.3%

TSHA-14.5%

% from 52W High

KLRA-58.9%

TSHA-38.5%

% from 52W Low

KLRA19.0%

TSHA21.6%

Asset Turnover (TTM)

KLRA0.00x

TSHA0.04x

FCF Yield (TTM)

KLRA0.0%

TSHA-9.2%

Earnings Yield (TTM)

KLRA-12.6%

TSHA-10.4%

Dividend Yield (TTM)

KLRAN/A

TSHAN/A

Rule of 40

KLRA0.0

TSHA-2,449.3

EV/GP/RG

KLRAN/A

TSHAN/A

Ticker research

View KLRA research View TSHA research

Metric	KLRA Kailera Therapeutics Inc	TSHA Taysha Gene Therapies Inc
Market & Valuation
Market Cap	$1.50B	$1.44B
Enterprise Value	$1.37B	$1.03B
Price	$11.61	$4.49
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	261.77x
EV/Sales	0.00x	187.75x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.20x	3.90x
P/FCF Ratio	N/A	N/A
EV/FCF	0.00x	-7.77x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	664.56x
Revenue & Growth
Revenue (TTM)	$0	$5M
Revenue Growth (YoY)	N/A	-32.3%
Forward Rev Growth	275.8%	1272.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-2833.6%
Net Margin (TTM)	0.0%	-2728.0%
FCF Margin (TTM)	N/A	-2417.0%
Net Income (TTM)	$-190M	$-150M
FCF (TTM)	$0	$-133M
EPS (TTM)	-$1.86	-$0.41
ROE (TTM)	0.0%	-5619.0%
ROA (TTM)	0.0%	-4184.0%
ROIC (TTM)	0.0%	-4729.0%
Financial Health
Cash	$130M	$455M
Debt	$0	$49M
Net Cash/Debt	$130M	$406M
Current Ratio (TTM)	11.11x	17.76x
Quick Ratio (TTM)	11.04x	17.57x
Debt/Equity (TTM)	0.00x	0.13x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.22	1.37
52W Performance	-55.3%	-11.3%
YTD Performance	-55.3%	-14.5%
% from 52W High	-58.9%	-38.5%
% from 52W Low	19.0%	21.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.04x
FCF Yield (TTM)	0.0%	-9.2%
Earnings Yield (TTM)	-12.6%	-10.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-2,449.3
EV/GP/RG	N/A	N/A
Ticker research	View KLRA research	View TSHA research

Valuation

P/S Ratio

KLRA

0.00x

TSHA

261.77x

EV/FCF

TSHA

-7.77x

KLRA

0.00x

Growth & revenue

Revenue Growth TTM

TSHA

-32.3%

Forward Revenue Growth

TSHA

1272.3%

KLRA

275.8%

Profitability & performance

Gross Margin

KLRA

0.0%

TSHA

0.0%

ROE

KLRA

0.0%

TSHA

-5619.0%

FCF Yield %

KLRA

0.0%

TSHA

-9.2%

52-Week Performance

TSHA

-11.3%

KLRA

-55.3%

Detailed metrics comparison

KLRA

Kailera Therapeutics Inc

TSHA

Taysha Gene Therapies Inc

Market Cap

KLRA$1.50B

TSHA$1.44B

Enterprise Value

KLRA$1.37B

TSHA$1.03B

Price

KLRA$11.61

TSHA$4.49

P/E Ratio

KLRAN/A

TSHAN/A

P/S Ratio

KLRA0.00x

TSHA261.77x

EV/Sales

KLRA0.00x

TSHA187.75x

EV/EBITDA

KLRA0.00x

TSHA0.00x

P/B Ratio

KLRA1.20x

TSHA3.90x

P/FCF Ratio

KLRAN/A

TSHAN/A

EV/FCF

KLRA0.00x

TSHA-7.77x

PEG Ratio

KLRAN/A

TSHAN/A

Forward P/E (NTM)

KLRAN/A

TSHAN/A

Forward P/S (NTM)

KLRAN/A

TSHA664.56x

Revenue (TTM)

KLRA$0

TSHA$5M

Revenue Growth (YoY)

KLRAN/A

TSHA-32.3%

Forward Rev Growth

KLRA275.8%

TSHA1272.3%

Gross Margin (TTM)

KLRA0.0%

TSHA0.0%

Operating Margin (TTM)

KLRA0.0%

TSHA0.0%

EBITDA Margin (TTM)

KLRA0.0%

TSHA-2833.6%

Net Margin (TTM)

KLRA0.0%

TSHA-2728.0%

FCF Margin (TTM)

KLRAN/A

TSHA-2417.0%

Net Income (TTM)

KLRA$-190M

TSHA$-150M

FCF (TTM)

KLRA$0

TSHA$-133M

EPS (TTM)

KLRA-$1.86

TSHA-$0.41

ROE (TTM)

KLRA0.0%

TSHA-5619.0%

ROA (TTM)

KLRA0.0%

TSHA-4184.0%

ROIC (TTM)

KLRA0.0%

TSHA-4729.0%

Cash

KLRA$130M

TSHA$455M

Debt

KLRA$0

TSHA$49M

Net Cash/Debt

KLRA$130M

TSHA$406M

Current Ratio (TTM)

KLRA11.11x

TSHA17.76x

Quick Ratio (TTM)

KLRA11.04x

TSHA17.57x

Debt/Equity (TTM)

KLRA0.00x

TSHA0.13x

Debt/Assets (TTM)

KLRA0.0%

TSHA0.0%

Interest Coverage (TTM)

KLRAN/A

TSHAN/A

Net Debt/EBITDA (TTM)

KLRA0.00x

TSHA0.00x

Beta

KLRA2.22

TSHA1.37

52W Performance

KLRA-55.3%

TSHA-11.3%

YTD Performance

KLRA-55.3%

TSHA-14.5%

% from 52W High

KLRA-58.9%

TSHA-38.5%

% from 52W Low

KLRA19.0%

TSHA21.6%

Asset Turnover (TTM)

KLRA0.00x

TSHA0.04x

FCF Yield (TTM)

KLRA0.0%

TSHA-9.2%

Earnings Yield (TTM)

KLRA-12.6%

TSHA-10.4%

Dividend Yield (TTM)

KLRAN/A

TSHAN/A

Rule of 40

KLRA0.0

TSHA-2,449.3

EV/GP/RG

KLRAN/A

TSHAN/A

Ticker research

View KLRA research View TSHA research

Metric	KLRA Kailera Therapeutics Inc	TSHA Taysha Gene Therapies Inc
Market & Valuation
Market Cap	$1.50B	$1.44B
Enterprise Value	$1.37B	$1.03B
Price	$11.61	$4.49
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	261.77x
EV/Sales	0.00x	187.75x
EV/EBITDA	0.00x	0.00x
P/B Ratio	1.20x	3.90x
P/FCF Ratio	N/A	N/A
EV/FCF	0.00x	-7.77x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	664.56x
Revenue & Growth
Revenue (TTM)	$0	$5M
Revenue Growth (YoY)	N/A	-32.3%
Forward Rev Growth	275.8%	1272.3%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-2833.6%
Net Margin (TTM)	0.0%	-2728.0%
FCF Margin (TTM)	N/A	-2417.0%
Net Income (TTM)	$-190M	$-150M
FCF (TTM)	$0	$-133M
EPS (TTM)	-$1.86	-$0.41
ROE (TTM)	0.0%	-5619.0%
ROA (TTM)	0.0%	-4184.0%
ROIC (TTM)	0.0%	-4729.0%
Financial Health
Cash	$130M	$455M
Debt	$0	$49M
Net Cash/Debt	$130M	$406M
Current Ratio (TTM)	11.11x	17.76x
Quick Ratio (TTM)	11.04x	17.57x
Debt/Equity (TTM)	0.00x	0.13x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	2.22	1.37
52W Performance	-55.3%	-11.3%
YTD Performance	-55.3%	-14.5%
% from 52W High	-58.9%	-38.5%
% from 52W Low	19.0%	21.6%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.04x
FCF Yield (TTM)	0.0%	-9.2%
Earnings Yield (TTM)	-12.6%	-10.4%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-2,449.3
EV/GP/RG	N/A	N/A
Ticker research	View KLRA research	View TSHA research